IMNM
Immunome, Inc.
Biotechnology
Market Cap$2.51B
5Y Perf.+95.5%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
IMNM vs DBVT
Revenue, margins, valuation, and 5-year total return — side by side.
DBVT
DBV Technologies S.A.
Biotechnology
Market Cap$1712.35T
5Y Perf.+39.8%
IMNM vs DBVT — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | IMNM | DBVT |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $2.51B | $1712.35T |
| Revenue (TTM) | $7M | $0.00 |
| Net Income (TTM) | $-212M | $-168M |
| Operating Margin | -32.3% | — |
| Total Debt | $4M | $22M |
| Cash & Equiv. | $653M | $194M |
IMNM vs DBVT — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
IMNM
DBVT
| Stock | Oct 20 | May 26 | Return |
|---|---|---|---|
| Immunome, Inc. (IMNM) | 100 | 195.5 | +95.5% |
| DBV Technologies S.… (DBVT) | 100 | 139.8 | +39.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: IMNM vs DBVT
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: IMNM leads in 3 of 6 categories, making it the strongest pick for growth and revenue expansion and recent price momentum and sentiment. DBV Technologies S.A. is the stronger pick specifically for profitability and margin quality and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
IMNM
Immunome, Inc.
The Growth Play
IMNM carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- Rev growth -23.2%, EPS growth 51.4%
- 65.0% 10Y total return vs DBVT's -87.0%
- Lower volatility, beta 2.08, Low D/E 0.6%, current ratio 14.69x
Best for: growth exposure and long-term compounding
DBVT
DBV Technologies S.A.
The Income Pick
DBVT is the clearest fit if your priority is income & stability and defensive.
- Dividend streak 0 yrs, beta 1.26
- Beta 1.26, current ratio 3.67x
- 0.3% margin vs IMNM's -30.6%
Best for: income & stability and defensive
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | IMNM | -23.2% revenue growth vs DBVT's -100.0% |
| Quality / Margins | DBVT | 0.3% margin vs IMNM's -30.6% |
| Stability / Safety | DBVT | Beta 1.26 vs IMNM's 2.08 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | IMNM | +198.7% vs DBVT's +110.4% |
| Efficiency (ROA) | IMNM | -52.4% ROA vs DBVT's -89.0% |
IMNM vs DBVT — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLIMNMLAGGINGDBVT
DBVTDBV Technologies S.A.
1leads
IMNMImmunome, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs DBVTMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
DBVT1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
IMNM6/6
Total Returns1Y, 3Y, 5Y total returns with dividends
IMNM6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
DBVT leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
IMNM and DBVT operate at a comparable scale, with $7M and $0 in trailing revenue.
| Metric | IMNMImmunome, Inc. | DBVTDBV Technologies … |
|---|---|---|
| RevenueTrailing 12 months | $7M | $0 |
| EBITDAEarnings before interest/tax | -$224M | -$112M |
| Net IncomeAfter-tax profit | -$212M | -$168M |
| Free Cash FlowCash after capex | -$201M | -$151M |
| Gross MarginGross profit ÷ Revenue | — | — |
| Operating MarginEBIT ÷ Revenue | -32.3% | — |
| Net MarginNet income ÷ Revenue | -30.6% | — |
| FCF MarginFCF ÷ Revenue | -28.9% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | -100.0% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +40.6% | +91.5% |
DBVT leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — IMNM and DBVT each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | IMNMImmunome, Inc. | DBVTDBV Technologies … |
|---|---|---|
| Market CapShares × price | $2.5B | $1712.35T |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $1712.35T |
| Trailing P/EPrice ÷ TTM EPS | -9.13x | -0.76x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 361.68x | — |
| Price / BookPrice ÷ Book value/share | 3.06x | 0.66x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — IMNM and DBVT each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
IMNM leads this category, winning 6 of 6 comparable metrics.
Profitability & Efficiency
IMNM delivers a -57.6% return on equity — every $100 of shareholder capital generates $-58 in annual profit, vs $-130 for DBVT. IMNM carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to DBVT's 0.13x.
| Metric | IMNMImmunome, Inc. | DBVTDBV Technologies … |
|---|---|---|
| ROE (TTM)Return on equity | -57.6% | -130.2% |
| ROA (TTM)Return on assets | -52.4% | -89.0% |
| ROICReturn on invested capital | -12.3% | — |
| ROCEReturn on capital employed | -54.4% | -145.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.01x | 0.13x |
| Net DebtTotal debt minus cash | -$650M | -$172M |
| Cash & Equiv.Liquid assets | $653M | $194M |
| Total DebtShort + long-term debt | $4M | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -189.82x |
IMNM leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
IMNM leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in IMNM five years ago would be worth $10,096 today (with dividends reinvested), compared to $3,090 for DBVT. Over the past 12 months, IMNM leads with a +198.7% total return vs DBVT's +110.4%. The 3-year compound annual growth rate (CAGR) favors IMNM at 56.8% vs DBVT's 6.2% — a key indicator of consistent wealth creation.
| Metric | IMNMImmunome, Inc. | DBVTDBV Technologies … |
|---|---|---|
| YTD ReturnYear-to-date | +6.6% | +4.9% |
| 1-Year ReturnPast 12 months | +198.7% | +110.4% |
| 3-Year ReturnCumulative with dividends | +285.2% | +19.7% |
| 5-Year ReturnCumulative with dividends | +1.0% | -69.1% |
| 10-Year ReturnCumulative with dividends | +65.0% | -87.0% |
| CAGR (3Y)Annualised 3-year return | +56.8% | +6.2% |
IMNM leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — IMNM and DBVT each lead in 1 of 2 comparable metrics.
Risk & Volatility
DBVT is the less volatile stock with a 1.26 beta — it tends to amplify market swings less than IMNM's 2.08 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. IMNM currently trades 80.3% from its 52-week high vs DBVT's 76.3% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | IMNMImmunome, Inc. | DBVTDBV Technologies … |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 2.08x | 1.26x |
| 52-Week HighHighest price in past year | $27.65 | $26.18 |
| 52-Week LowLowest price in past year | $7.15 | $7.53 |
| % of 52W HighCurrent price vs 52-week peak | +80.3% | +76.3% |
| RSI (14)Momentum oscillator 0–100 | 54.0 | 48.1 |
| Avg Volume (50D)Average daily shares traded | 1.1M | 252K |
Evenly matched — IMNM and DBVT each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates IMNM as "Buy" and DBVT as "Buy". Consensus price targets imply 131.8% upside for DBVT (target: $46) vs 66.0% for IMNM (target: $37).
| Metric | IMNMImmunome, Inc. | DBVTDBV Technologies … |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $36.83 | $46.33 |
| # AnalystsCovering analysts | 10 | 15 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
IMNM leads in 2 of 6 categories (Profitability & Efficiency, Total Returns). DBVT leads in 1 (Income & Cash Flow). 2 tied.
Best OverallImmunome, Inc. (IMNM)Leads 2 of 6 categories
Loading custom metrics...
IMNM vs DBVT: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is IMNM or DBVT a better buy right now?
Analysts rate Immunome, Inc.
(IMNM) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — IMNM or DBVT?
Over the past 5 years, Immunome, Inc.
(IMNM) delivered a total return of +1. 0%, compared to -69. 1% for DBV Technologies S. A. (DBVT). Over 10 years, the gap is even starker: IMNM returned +65. 0% versus DBVT's -87. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — IMNM or DBVT?
By beta (market sensitivity over 5 years), DBV Technologies S.
A. (DBVT) is the lower-risk stock at 1. 26β versus Immunome, Inc. 's 2. 08β — meaning IMNM is approximately 65% more volatile than DBVT relative to the S&P 500. On balance sheet safety, Immunome, Inc. (IMNM) carries a lower debt/equity ratio of 1% versus 13% for DBV Technologies S. A. — giving it more financial flexibility in a downturn.
04Which is growing faster — IMNM or DBVT?
On earnings-per-share growth, the picture is similar: Immunome, Inc.
grew EPS 51. 4% year-over-year, compared to -347. 5% for DBV Technologies S. A.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — IMNM or DBVT?
DBV Technologies S.
A. (DBVT) is the more profitable company, earning 0. 0% net margin versus -30. 6% for Immunome, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: DBVT leads at 0. 0% versus -32. 3% for IMNM. At the gross margin level — before operating expenses — IMNM leads at 0. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — IMNM or DBVT?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is IMNM or DBVT better for a retirement portfolio?
For long-horizon retirement investors, DBV Technologies S.
A. (DBVT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Immunome, Inc. (IMNM) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (DBVT: -87. 0%, IMNM: +65. 0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between IMNM and DBVT?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.